Roivant Sciences Ltd. is actively pursuing business development deals to build out its late-stage pipeline, with a goal of spending some of the cash it earned on the $7.1bn sale of Telavant to Roche Holding AG last year. CEO Matt Gline told investors during the company’s third quarter sales and earnings call on 13 February that Roivant hopes to bring in “multiple” programs over the next year that would be “transformative” to the late-stage pipeline.
Key Takeaways
- Roivant is looking to bring in new assets to build out its late-stage pipeline, planning to use some of the windfall from the sale of Telavant to Roche last year.
- The company is therapeutic area agnostic when it comes to business development, seeking assets that are undervalued by others
“The general sort of scope of things we’re looking at, I’d say, match the kinds of deals that we’ve done before, so partnerships or
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
